MedX was able to attract fundingMedX was able to attract investors despite the current share price. Included among the investors was Forest Lane Holdings Limited, a company controlled by David Hennigar, a director of the Company, which subscribed for ten Series III Notes for a total of $500,000. I think the current share price is based on the belief that MedX is going out of business and that the current contracts are not producing any revenue. Over the next quarter if this proves to be a false belief, then I would expect the share price to have a solid rebound. The company is currently trading at 10% of tax-loss value, so for $4 million, you can buy a complete secure teledermatology platform, a Class 2 medical device with regulatory clearances in 38 countries. This is either extremely undervalued or a tax write-off.